Showing papers by "Carl Erik Mogensen published in 2014"
The George Institute for Global Health1, University of Sydney2, Baker IDI Heart and Diabetes Institute3, Bond University4, Utrecht University5, Université de Montréal6, University of Melbourne7, University of Sheffield8, University of Milan9, University of Paris10, University of Oxford11, Aarhus University12, University College London13, Johns Hopkins University14
TL;DR: There was no evidence that intensive glucose control during the ADVANCE factorial trial led to long-term benefits with respect to mortality or macrovascular events.
Abstract: Background In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perindopril and indapamide reduced mortality among patients with type 2 diabetes, but intensive glucose control, targeting a glycated hemoglobin level of less than 6.5%, did not. We now report results of the 6-year post-trial follow-up. Methods We invited surviving participants, who had previously been assigned to perindopril–indapamide or placebo and to intensive or standard glucose control (with the glucose-control comparison extending for an additional 6 months), to participate in a post-trial follow-up evaluation. The primary end points were death from any cause and major macrovascular events. Results The baseline characteristics were similar among the 11,140 patients who originally underwent randomization and the 8494 patients who participated in the post-trial follow-up for a median of 5.9 years (blood-pressure–lowering comparison) or ...
492 citations